Today's MarketStats on Healthcare companies include: MIV Therapeutics, Inc. (OTC BB: MIVT.OB), Johnson & Johnson (NYSE: JNJ), Medtronic Inc. (NYSE: MDT), Boston Scientific (NYSE: BSX) and Angiotech Pharmaceuticals Inc. (NasdaqGS: ANPI).
MIV Therapeutics, Inc. (OTC BB: MIVT.OB) MIV Therapeutics is an advanced stage, research and development company pursuing the commercialization of the next-generation biocompatible coatings for stents and other medical devices, and advanced drug delivery systems with the intent of providing healing solutions for cardiovascular disease and other medical conditions.
Although MIV is near its 52 week low, the previous trading day saw an increase of 6.25% on 39% more trading volume than their 3 month moving average.
To view a complete profile on MIV Therapeutics, Inc., visit our financial courier at StockUpTicks.com
Johnson & Johnson (NYSE: JNJ) Johnson & Johnson engages in the manufacture and sale of various products in the health care field worldwide. The company was founded in 1885 and is based in New Brunswick, New Jersey.
JNJ has typical profitability characteristics of a company in the Major Drugs industry. While it is better than most at converting revenues to profits on a net and operating margin basis, its gross margin is on par with the industry norm.
JNJ saw earnings decline in spite of positive revenue growth during the past twelve months. Additionally, the average company in the Major Drugs industry was able to grow earnings at a faster rate than JNJ.
Medtronic Inc. (NYSE: MDT) Medtronic, Inc. is engaged in medical technology, alleviating pain, restoring health, and extending life for people around the world. The company was founded in 1949 and is headquartered in Minneapolis, Minnesota.
Because MDT is in the Medical Equipment & Supplies industry and has positive earnings, the PEG, PE, and Price to Book ratios are the most appropriate valuation measures. The Price to Sales ratio is less instructive than the PEG or PE since the company has positive earnings. Therefore MDT seems fairly valued with a PEG of 1.7524 that is inline with the Medical Equipment & Supplies industry median of 1.73, which is supported by a PE of 25.0992 that is also inline with the industry median of 23.43.
Based on its gross margin, operating margin, and net margin, MDT converts a larger percentage of its revenues to profits than most other companies in the Medical Equipment & Supplies industry. Furthermore, the company is profitable with an operating margin of 21.16%.
Boston Scientific (NYSE: BSX) Boston Scientific Corporation engages in the development, manufacture, and marketing of medical devices that are used in interventional medical specialties worldwide. The company offers its products in three groups: Cardiovascular, Endosurgery, and Neuromodulation. The company was founded in 1979 and is headquartered in Natick, Massachusetts.
Earnings growth at BSX outpaced revenue growth over the trailing twelve months. This is a trend that is not sustainable if profits are to continue to grow at this rate. However, this result was better than that of the average company in the Medical Equipment & Supplies industry.
BSX has a debt to total capital ratio of 35.17% which is in-line with the Medical Equipment & Supplies industry's norm. Its Interest Coverage ratio is only -3.14, which means that it does not earn enough from day-to-day operations to service its debt. However, the Quick ratio shows that the balance sheet can make up for this shortfall as there are enough liquid assets to satisfy current obligations.
Angiotech Pharmaceuticals Inc. (NasdaqGS: ANPI) Angiotech Pharmaceuticals, Inc. operates as a specialty pharmaceutical and medical device company. It discovers, develops, and markets technologies and medical products for local diseases and complications associated with medical device implants, surgical interventions, and acute injury. The company was founded in 1989 and is headquartered in Vancouver, Canada.
Because the earnings of ANPI are not available, the Price to Sales and Price to Book ratios are the most appropriate valuation measures. Therefore ANPI seems valued at a discount with a Price to Sales ratio of 0.9861, one of the lowest in the Biotechnology & Drugs industry, which is supported by a Price to Book of 0.6392 that is also among the lowest in the industry.
ANPI is one of the most highly leveraged companies in the Biotechnology & Drugs industry and has a Debt to Total Capital ratio of 56.56%. Additionally, the percentage of debt used in its capital structure grew this year. Its Interest Coverage ratio is only -0.56, which means that it does not earn enough from day-to-day operations to service its debt. However, the Quick ratio shows that the balance sheet can make up for this shortfall as there are enough liquid assets to satisfy current obligations.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report.
This report is neither a solicitation to buy nor an offer to sell securities but is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor, analyst or licensed broker dealer and this report is not investment advice. MP has been paid twenty four thousand dollars by MIV Therapeutics Inc. for preparation and distribution of this report and other services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment